Table 1 Designs of the six studies included in the sputum analysis
Study number [ref.]DesignTreatment (moxifloxacin and comparator)#Patients nPatients with a causative organism n
84 [6]Prospective, multicentre, multinational, nonblind, randomised study in EuropeMoxifloxacin, 400 mg q.d. for 5 days; amoxicillin/clavulanate, 625 mg t.i.d. for 7 days575251
100033 [7]Prospective, randomised, double-blind, multicentre study in the USAMoxifloxacin, 400 mg q.d. for 5 days; moxifloxacin, 400 mg q.d. for 10 days; clarithromycin, 500 mg b.i.d. for 10 days926491
100034Prospective, randomised, double-blind, multicentre study in the USA and CanadaMoxifloxacin, 400 mg q.d. for 10 days; moxifloxacin, 200 mg q.d. for 10 days; cefuroxime axetil, 500 mg b.i.d. for 10 days682274
100160 [8]Prospective, randomised, double-blind, multicentre study in the USA and CanadaMoxifloxacin, 400 mg q.d. for 5 days; azithromycin, 250 mg q.d. (500 mg on day 1) for 5 days567280
100243 [9]Prospective, randomised, double-blind, multicentre study in the USAMoxifloxacin, 400 mg q.d. for 5 days; levofloxacin, 500 mg q.d. for 7 days594315
240017 [10]Prospective, randomised, double-blind, multicentre study in EuropeMoxifloxacin, 400 mg q.d. for 5 days; clarithromycin, 500 mg b.i.d. for 7 days745287
  • #: all treatments were administered orally; : data held on file by Bayer Schering Pharma.